Lilly to pay $8bn for Loxo Oncology as cancer M&A soars
Eli Lilly, the US pharmaceuticals company, has agreed to buy Loxo Oncology for around $8bn, as big ticket consolidation in the drug sector continues apace.
Eli Lilly has agreed to pay $235 a share in cash for Loxo, a biopharmaceuticals company that makes medicines for certain types of cancer. The price is a 68% premium to Loxo's closing price on January 4.
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org